California, USA (CU)_ Merck (MSD) has agreed to purchase all of Acceleron Pharma’s remaining shares for $11.5 billion in cash. As part of the deal, Merck’s subsidiary will begin a tender offer for Acceleron stock at a price of $180 per share. This Merck subsidiary will be merged into Acceleron after the acquisition is completed. Merck anticipates that this collaboration will strengthen its cardiovascular program. The remaining Acceleron common stock will be cancelled and transformed into the right to receive the transaction price in the tender offer, which will be $180 per share.
Merck CEO and President Rob Davis expressed optimism about the acquisition. He said, “Strategic business development is a top priority for Merck as we look to drive sustainable growth and further bolster and…
